Excel Industries Limited has informed the Exchange about Transcript
EXCELINDUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Excel Industries held its maiden earnings call, reporting FY25 standalone revenue of Rs 978 crore (up 18% YoY) and a sharp recovery in profitability, with EBITDA at Rs 121 crore (up ~400% YoY) and PAT at Rs 84 crore (up 453% YoY). FY25 EBITDA margin stood at 12.3%, up from 2.9% in FY24, supported by demand revival and better product mix. Q4 FY25 revenue was Rs 248 crore (up 26% QoQ) with EBITDA of Rs 20 crore. Management guided a medium-term EBITDA margin band of 13–15% and announced a Rs 200–300 crore capex plan over the next 3 years (versus Rs 40–50 crore annual run-rate earlier), including a Rs 10.3 crore biocide capacity expansion (doubling capacity, commissioning H2 FY26), a new R&D centre (~Rs 15 crore, operational H1 FY26), and supplies from a long-term multinational contract beginning Q2 FY26.
Strong FY25 turnaround and management's 3-year growth capex plan signal a constructive outlook, but absence of specific FY26 revenue guidance and segment-level margin disclosure may cap near-term upside. Shareholders should watch biocide capacity ramp-up, the multinational contract contribution, and execution of the Rs 200–300 crore capex plan for margin expansion toward the 13–15% guided band.